WALL STREET JOURNAL reports on NPC success!

In its July 24, 2010 edition (click here for full article), THE WALL STREET JOURNAL reported that NPC disease has been selected as one of only three diseases initially selected for a new program at the National Institutes of Health called Therapeutics for Rare and Neglected Diseases or TRND.  Due to the initial success of SOAR-NPC, TRND will be providing SOAR-NPC with a 5th principal investigator, a second clinical researcher for drug trials and 2 project managers with pharmaceutical industry experience to help guide the SOAR-NPC team toward its goal of a drug cocktail for NPC. Priceless!

Posted in Announcements, DART News, Niemann-Pick Type C News